Home Companies Catalysts Deep Dives
Brilinta ticagrelor APPROVED
Drug Profile
ModalitySmall molecule
RouteORAL
Therapy AreaCVRM
Launch2011-07-20
US LOE2025-02-19
Peak Sales Est$1500M
Formulations[{"id":"brilinta-oral","doses":"60mg, 90mg","route":"PO","device":"Tablet","setting":"PATIENT_SELF",
Companies
AZN (ORIGINATOR)100%
Mechanism: P2Y12 inhibitor
Expert: Reversible, direct-acting P2Y12 receptor antagonist that inhibits ADP-mediated platelet aggregation without requiring metabolic activation.
Everyday: Prevents blood clots by stopping platelets from sticking together.
Targets: ["P2Y12"]
Revenue History
PeriodRevenue ($M)
2023$1,274M
2024$1,156M
Q1 2025$270M
Programs (2)
IndicationStageKey StudyRegional Status
Prior MIAPPROVEDPEGASUS[{"stage":"APPROVED","region":"US","approval_date":"2015-09-09"}]
ACSAPPROVEDPLATO[{"stage":"APPROVED","region":"US","approval_date":"2011-07-20"},{"stage":"APPRO
Notes
P2Y12 inhibitor. LOE headwind.
Data from Supabase · Updated 2026-03-24